The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma

The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma

IntroductionImmune checkpoint inhibition (ICI) plus bevacizumab (BEV) is the standard first-line treatment for unresectable hepatocellular carcinoma (uHCC). We aimed to assess the efficacy and safety of ICI plus bevacizumab and ICI plus receptor tyrosine kinase inhibitor (TKI) in this patient popula...

Full description

Bibliographic Details
Main Authors: Hui Zeng, Qi Xu, Jinyu Wang, Xiaoqing Xu, Jun Luo, Lei Zhang, Cong Luo, Jieer Ying, Jingjing Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Immunology
Subjects:
hepatocellular carcinoma
first-line treatment
immune checkpoint inhibition
VEGF receptor tyrosine kinase inhibitors
bevacizumab
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1073133/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1073133/full

Similar Items